IsoRay, Inc. (NYSEAMERICAN:ISR)’s share price gapped up prior to trading on Friday . The stock had previously closed at $0.82, but opened at $0.84. IsoRay shares last traded at $0.88, with a volume of 2,735,089 shares.

Separately, Zacks Investment Research downgraded IsoRay from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th.

The firm has a 50 day moving average of $0.34.

IsoRay (NYSEAMERICAN:ISR) last issued its quarterly earnings data on Tuesday, November 12th. The healthcare company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The company had revenue of $2.32 million during the quarter, compared to analysts’ expectations of $2.23 million.

In other IsoRay news, CEO Lori A. Woods bought 150,000 shares of IsoRay stock in a transaction dated Friday, November 15th. The stock was bought at an average cost of $0.39 per share, with a total value of $58,500.00. Over the last ninety days, insiders bought 210,000 shares of company stock valued at $81,900.

A hedge fund recently raised its stake in IsoRay stock. Vanguard Group Inc. increased its holdings in shares of IsoRay, Inc. (NYSEAMERICAN:ISR) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,594,907 shares of the healthcare company’s stock after acquiring an additional 169,100 shares during the quarter. Vanguard Group Inc. owned about 2.37% of IsoRay worth $654,000 at the end of the most recent reporting period.


IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Recommended Story: Sell-Side Analysts

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.